Accumulated CV data from SGLT2i outcomes trials
Summary of clinical and scientific topics discussed at EASD 2020 congress
Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology
Effects of empagliflozin on physical activity and compensatory appetite responses in people with type 2 diabetes: the SEESAW trial
Highlights of the 2019 EASD Congress
DAPA HF : The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial
Early intervention with oral semaglutide and long term safety
VERIFY and CONCLUDE study
Clinical properties and differences between GLP-1 agonists
Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes
Diabetic retinopathy: Is the eye a mirror of the brain?
Cardiovascular mode of action of GLP-1 receptor agonists
Exploring the effects of SGLT2 inhibition in ongoing clinical trials
Cardiovascular outcome trials: putting recent updates into perspective
Clinical insights into recent EXAMINE trial data: an evolving story
Medical Devices in Diabetes
Will SGLT2-inhibitors change the landscape?
Innate immunity in pancreatic islet inflammation
The artificial beta cell. When will the dream become reality?
Observational study of insulin pump treatment
The evidence for metformin is unclear?
The ORIGIN Study And Legacy Effects
EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk
Principal investigator presenting the results of EMPA-REG OUTCOME trial
Joint Statement on Diabetes Self-Management Education
50 years of clinical research in diabetes
50 years in treatment of diabetes complications
50 years of diabetes treatment
75 years with diabetes – a patient’s perspective